Nephrogenic systemic fibrosis

Pediatric Radiology

Volumn 38, Issue 1 SUPPL., 2008, Pages

  Martin, Diego R ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Children; Gadolinium; MRI; Nephrogenic systemic fibrosis; Renal insufficiency

Indexed keywords

GADODIAMIDE; GADOLINIUM;

CLINICAL PRACTICE; CONFERENCE PAPER; DIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SKIN BIOPSY; SKIN DISEASE;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN;

EID: 37549037896     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-007-0589-8     Document Type: Conference Paper

References (32)

1. Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000-1001
2. Cowper SE, Su LD, Bhawan J et al (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383-393
3. Gibson SE, Farver CF, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130:209-212
4. Daram SR, Cortese CM, Bastani B (2005) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 46:754-759
5. Khurana A, Runge VM, Narayanan M et al (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 42:139-145
6. LeBoit PE (2003) What nephrogenic fibrosing dermopathy might be. Arch Dermatol 139:928-930
7. Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785-790
8. Cowper SE, Bucala R (2003) Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25:358
9. Mackay-Wiggan JM, Cohen DJ, Hardy MA et al (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48:55-60
10. Grobner T (2006) Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104-1108
11. Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362
12. Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148-157
13. Broome DR, Girguis MS, Baron PW et al (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 188:586-592
14. Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27-30
15. High WA, Ayers RA, Chandler J et al (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21-26
16. High WA, Ayers RA, Cowper SE (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:710-712
17. DeHoratius DM, Cowper SE (2006) Nephrogenic systemic fibrosis: an emerging threat among renal patients. J Am Acad Dermatol 19:191-194
18. Maloo M, Abt P, Kashyap R et al (2006) Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 6:2212-2217
19. Prince MR, Erel HE, Lent RW et al (2003) Gadodiamide administration causes spurious hypocalcemia. Radiology 227:639-646
20. Doweiko JP, Nompleggi DJ (1991) The role of albumin in human physiology and pathophysiology, Part III: albumin and disease states. JPEN J Parenter Enteral Nutr 15:476-483
21. Doweiko JP, Nompleggi DJ (1991) Role of albumin in human physiology and pathophysiology. JPEN J Parenter Enteral Nutr 15:207-211
22. Bayer HealthCare Pharmaceuticals (2007) Magnevist safety information. http://www.imaging.bayerhealthcare.com/html/magnevist/nsf_nfd.html?WT.mc_id= berleximaging.com. Cited 9 August 2007
23. Cowper SE (2007) Nephrogenic fibrosing dermopathy (NFD/NSF website). 2001-2007. http://www.icnfdr.org/. Cited 9 August 2007
24. Aydingoz U (2006) The need for radiologists' awareness of nephrogenic systemic fibrosis. Diagn Interv Radiol 12:161-162
25. Center for Drug Evaluation and Research (2007) Public Health Advisory. Update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy. FDA, Center for Drug Evaluation and Research. http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm. Cited 9 August 2007
26. Cowper SE, Boyer PJ (2006) Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 8:151-157
27. Galan A, Cowper SE, Bucala R (2006) Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18:614-617
28. Baron PW, Cantos K, Hillebrand DJ et al (2003) Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25:204-209
29. Jimenez SA, Artlett CM, Sandorfi N et al (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50:2660-2666
30. Levine JM, Taylor RA, Elman LB et al (2004) Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 30:569-577
31. Mendoza FA, Artlett CM, Sandorfi N et al (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238-249
32. Swaminathan S, Ahmed I, McCarthy JT et al (2006) Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145:234-235